NORLUTATE Drug Patent Profile
✉ Email this page to a colleague
When do Norlutate patents expire, and when can generic versions of Norlutate launch?
Norlutate is a drug marketed by Parke Davis and is included in one NDA.
The generic ingredient in NORLUTATE is norethindrone acetate. There are twenty-six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the norethindrone acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Norlutate
A generic version of NORLUTATE was approved as norethindrone acetate by BARR on May 25th, 2001.
Summary for NORLUTATE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 62 |
| Clinical Trials: | 1 |
| Patent Applications: | 3,938 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | NORLUTATE at DailyMed |
Recent Clinical Trials for NORLUTATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Cooperative Study Group A for Hematology | Phase 3 |
US Patents and Regulatory Information for NORLUTATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parke Davis | NORLUTATE | norethindrone acetate | TABLET;ORAL | 012184-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
